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Abstract
Introduction: Eicosanoids and oxidants play an important role in inflammation,
but their role in chronic obstructive pulmonary disease (COPD) is uncertain. In
this study we hypothesized that levels of exhaled leukotrienes, prostaglandins
and biomarkers of oxidative stress are increased in infectious exacerbations of
COPD and that they decrease after antibiotic therapy. 
Material and methods: Cysteinyl-leukotrienes (LTs), leukotriene B4 (LTB4),
prostaglandin E4, hydrogen peroxide (H2O2) and 8-isoprostane were measured
in exhaled breath condensate (EBC) in 16 COPD patients with infectious exac-
erbations (mean age 64 ±12 years, 13 male) on day 1, during antibiotic therapy
(days 2-4), 2-4 days after therapy and at a follow-up visit when stable (21-28
days after therapy). 
Results: There was a significant fall in concentration of cys-LTs, LTB4 and 8-iso-
prostane at visit 3 compared to day 1 (cys-LTs: 196.5 ±38.4 pg/ml vs. 50.1 ±8.2 pg/ml,
p < 0.002; LTB4: 153.6 ±25.5 pg/ml vs. 71.9 ±11.3 pg/ml, p < 0.05; 8-isoprostane: 
121.4 ±14.6 pg/ml vs. 56.1 ±5.2 pg/ml, p < 0.03, respectively). Exhaled H2O2 was
higher on day 1 compared to that at visits 2 and 3 (0.74 ±0.046 μM vs. 0.52
±0.028 μM and 0.35 ±0.029 μM, p < 0.01 and p < 0.01, respectively). Exhaled
PGE2 levels did not change during exacerbations of COPD. Exhaled eicosanoids
and H2O2 in EBC measured at the follow-up visit (stable COPD) were signifi-
cantly higher compared to those from healthy subjects. 
Conclusions: We conclude that eicosanoids and oxidants are increased in infec-
tious exacerbations of COPD. They are also elevated in the airways of stable
COPD patients compared to healthy subjects.
Key words: chronic obstructive pulmonary disease, exhaled eicosanoids, 8-iso-
prostane, exhaled breath condensate.
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by the
progressive development of airflow limitation associated with chronic inflam-
mation [1]. The most important pathological changes are found within the
small airways and are characterized by an increased number of macrophages,
neutrophils and CD8+ T cells, features which are also found in bronchial
biopsies [1]. There is also an increase in macrophages and neutrophils in
bronchoalveolar lavage fluid and induced sputum [2]. Furthermore, increased
neutrophils in the airways are related to the rate of progression of airway
obstruction [3]. Smoking, which is the most important risk factor, increases
neutrophil recruitment to the lungs [4], possibly by stimulating bronchial
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epithelium and macro  phages to produce the neu-
trophil chemoattractant interleukin-8 (IL-8) [5]. More-
over, levels of IL-8 and leukotriene B4 (LTB4), which
are also chemotactic for neutrophils, are increased
in the sputum of patients with COPD [6]. In contrast
to asthma, eosinophils are not increased except dur-
ing exacerbations [7]. 
There is a complex interaction between cells and
mediators in COPD, resulting in progressive changes
in small airways and parenchymal damage [1]. It is
postulated that macrophages play a critical role,
since they are 5 to 10 times increased and when
activated are capable of producing all the patho-
logical changes of COPD. They are activated by cig-
arette smoke to release neutrophil chemoattrac-
tants and other mediators of inflammation
including eicosanoids [5].
There is overwhelming evidence that oxidative
stress may have an important role in COPD [8].
Hydrogen peroxide (H2O2) levels in exhaled breath
condensate of patients with COPD are increased,
particularly during exacerbations [9]. Plasma antiox-
idant capacity is decreased in patients with acute
exacerbations of COPD [10]. It has also been clear-
ly shown that oxidative overburden leads to lipid
peroxidation in the airway of patients with COPD
as reflected by greater exhaled ethane and 8-iso-
prostane levels compared to healthy subjects [11]. 
Eicosanoids are important inflammatory media-
tors in asthma, but their role in COPD remains unclear.
The LTB4 was detected in nasal lavage [12], sputum
and BAL fluid in patients with stable COPD and lev-
els of LTB4 in sputum and BAL correlate with other
markers of inflammation such as myeloperoxidase
and elastase activity [13]. Moreover, serum LTB4 lev-
els in patients with COPD are higher than in healthy
subjects [14]. In contrast, Piperno et al. demonstrat-
ed that LTC4 but not LTB4 is detectable in the plasma
of patients with COPD [15]. However, plasma levels
of leukotrienes are difficult to interpret due to release
from inflammatory cells and metabolism. Cys-LTs are
potent bronchoconstrictors and play an important
role in asthma, particularly in the aspirin-sensitive
type [16]. They have also been detected in the spu-
tum of patients with chronic bronchitis [17]. The
prostaglandin E2 (PGE2) relaxes airway smooth mus-
cles and exerts potent anti-inflammatory activity [18].
It is postulated that the failure in a PGE2-braking
mechanism with increased sensitivity to inhibition by
NSAIDs contributes to the overproduction of cys-LTs
in aspirin-induced asthmatic patients [16]. 
Exhaled breath condensate (EBC) provides
a non-invasive and easy-to-perform means of look-
ing at the local inflammatory process in the airways,
without the need to undertake invasive procedures,
such as bronchoscopy. Most of the studies to
explore the role of eicosanoids in COPD have used
invasive techniques or the assessment of media-
tors and their metabolites in plasma or urine. Con-
centrations of eicosanoids in these biological fluids
are more likely to reflect systemic, rather than res-
piratory tract inflammation. An increasing body of
evidence suggests that EBC is a useful way to mon-
itor markers of inflammation and oxidative stress
in various respiratory tract diseases.
Exhaled cys-LTs and PGE2 are markers of inflam-
mation in the airways. The LTB4 plays an important
role in neutrophil recruitment and activation at the
site of inflammation. 8-isoprostane and H2O2 are
biomarkers of oxidative stress in breath conden-
sate in inflammatory airway diseases such as asth-
ma, COPD, and cystic fibrosis [19].
Accordingly, the aim of this study was to deter-
mine eicosanoids, 8-isoprostane and H2O2 at vari-
ous time points in COPD patients hospitalized for
an infectious exacerbation of COPD and treated
with antibiotics, and to investigate the relationship
between these inflammatory markers and clinical
variables (airflow limitation and respiratory failure). 
Material and methods
Study population
Sixteen patients with severe infectious exacerba-
tions of COPD (mean age 64 ±12 years, 13 male), and 
13 healthy age-matched controls (mean age 57 ±19
years, 10 male) were recruited for this study (Table I).
Patients from the control group had no history of any
respiratory disease or respiratory infection, they were
non-smokers and they did not suffer from any other
disease that could exclude them from the study. The
COPD was diagnosed by a history of cough and spu-
tum production for more than 2 consecutive years
and for most days in a consecutive 3-month period
and spirometry criteria according to GOLD standards
[1]. Exacerbation of COPD was defined as “an event
in the natural course of the disease characterized by
a change in the patient’s baseline dyspnoea, cough
and/or sputum that is beyond normal day-to-day vari-
ations, is acute in onset and may warrant a change
in regular medication” [1]. The severity of exacerba-
tion was assessed on the basis of patients’ history
before the exacerbation (duration of worsening, pre-
vious hospitalisations, previous treatment), comor-
bidities, symptoms, physical diagnosis, and meas-
urements of arterial blood gases [1]. In this study
exacerbation of COPD was characterized by increased
purulent sputum together with increased dyspnoea
and cough. Other inclusion criteria were forced expi-
ratory volume in 1 s (FEV1) > 50% predicted, at least
3 episodes of exacerbation of COPD in the past year
requiring treatment with an antibiotic, and age ≥ 40
years. Exclusion criteria were a known or suspected
hypersensitivity to cephalosporins or macrolides, cys-
tic fibrosis, bronchiectasis or active pulmonary malig-
nancies, immunocompromised patients, and patientsArch Med Sci 2, April / 2012 279
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receiving systemic steroids. Due to exacerbation all
patients were treated with inhaled steroids (1000 μg
of budesonide or equivalent as an alternative to sys-
temic steroids [1]) and they had been immediately
admitted to the hospital. They continued steroid ther-
apy through the entire hospitalisation (inhaled
steroids with or without systemic steroids at a dose
of < 30 mg per day of prednisone or equivalent up to
7 days). Bronchodilators were allowed in the study
including inhaled or nebulized ipratropium bromide
and albuterol. Long-acting β2-agonists were used (for-
moterol up to 54 μg/day). All subjects completed an
informed written consent form, and the study was
approved by the Ethics Committee of the Medical Uni-
versity of Lodz. 
Study design
This was a randomized, open label, controlled, sin-
gle-centre study to compare changes in exhaled
eicosanoids and H2O2 in patients with exacerbation
of COPD treated for at least 7 days with oral rox-
ithromycin (7 patients, 150 mg, twice daily) or oral
cefuroxime axetil (9 patients, 500 mg twice daily) ran-
domly allocated (1 : 1) to the patients. Average dura-
tion of treatment was 7.3 ±0.6 days. Patients were
assessed, exhaled breath condensate was obtained,
and spirometry and arterial blood gases measure-
ments were done at the baseline visit (visit 1), during
therapy (days 2-4), at the end of therapy (2-4 days
after therapy) and at a follow-up visit (21-28 days after
therapy) (Table II). A sputum specimen for bacterio-
logical evaluation (gram staining, culture and sus-
ceptibility testing) was collected at visit 1. 
Exhaled breath condensate
Breath condensate samples were obtained using
a condensing tubing system, as previously
described [20]. Briefly, patients were asked to
breathe through the collection tube for 15 min. The
collection part of the tube was covered with dry ice.
No Age Body  WBC Neutrophil Current  Cumulative  Pathogen FEV1 FEV1/FVC
[years] temperature absolute smoking smoking[ %  pred.] [%]
[°C] status habit
[cigarettes/[ p ack years]
day]
1. ♂ 55 38.4 8.4 5.43 Non-smoking 30 Staphylococcus 69.5 65
aureus,
Streptococcus
pneumoniae
2. ♀ 70 36.6 12.3 8.08 20 50 S. aureus, 56.9 60
S. pneumoniae
3. ♂  58 38.2 9.2 6.6 10 15 S. pneumoniae 74.3 69
4. ♀ 76 38.0 10.8 8.55 20 30 S. pneumoniae 55.3 58
5. ♂  60 37.8 13.5 10.52 20 45 No pathogen isolated 69.9 67
6. ♂  58 36.0 7.6 5.29 20 20 Candida sp. 72.1 66
7. ♂  66 36.8 6.9 5.33 25 40 S. pneumoniae 49.9 57
8. ♂  56 38.6 7.8 4.77 20 30 S. aureus 68.6 63
9. ♂  60 38.3 11.2 7.85 40 120 Klebsiella 54.9 60
pneumoniae
10. ♂ 77 38.0 11.6 8.83 40 90 S. aureus 66.3 67
11. ♂  43 38.0 18.7 17.15 Non-smoking 45 S. aureus 45.7 50
12. ♂  56 37.2 16.1 14.59 20 60 Proteus vulgaris 79.9 68
13. ♂  57 38.0 8.2 5.64 20 30 S. aureus. 59.9 63
S. pneumoniae
14. ♂  77 38.0 4.7 3.92 15 37.5 S. aureus.6 2 6 0
S. pneumoniae,
Pseudomonas
aeruginosa
15. ♂  71 37.6 8.7 5.09 20 40 S. pneumoniae 52.5 59
16. ♀ 69 36.4 12.1 10.2 Non-smoking 35 Escherichia coli 53.6 61
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The temperature in the tube vicinity ranged from
–43°C to –32°C and allowed collection of all vapours
and droplets present in the exhaled air. At the end
of the collection, the tube was removed from the
container and 2-6 ml aliquots of condensate were
transferred to Eppendorf tubes and stored at –80°C
for not more than 4 weeks. Due to the impact of
cigarette smoke on oxidants and eicosanoids pres-
ent in exhaled breath, our patients refrained from
smoking for at least 12 h before measurement. It
was easy because they were in exacerbation of
COPD and most of them did not even smoke due
to their symptoms. 
Measurement of leukotrienes
Cys-LTs concentration in breath condensate was
measured using a specific enzyme immunoassay
(EIA) kit (Cayman Chemical, Ann Arbour, MI). The
antiserum used in this assay has 100% cross-reac-
tivity with LTC4 and LTD4, 67% with LTE4, and 
< 0.01% each with 15-HETE, 12-HETE, LTB4, PGF2. The
detection limit of the assay is 13 pg/ml. This kit has
been used to measure concentrations of cys-LTs in
rat and human urine, plasma, and BAL fluid [12, 21]. 
The LTB4 was measured using the EIA kit (Cay-
man Chemical) in breath condensate. The anti-
serum used in this assay has 100% cross-reactivi-
ty with LTB4, 39% with 6-trans LTB4, and < 0.01%
each with LTC4,L T E 4,L T D 4, and LTF4, and a detec-
tion limit of 4.43 pg/ml. 
Measurement of immunoreactive 
8-isoprostane
8-isoprostane concentration in breath conden-
sate was measured using an EIA kit (Cayman Chem-
ical). The antiserum used in this assay has 100%
cross-reactivity with 8-epi-PGF2α, 0.2% each with
PGF2α, PGF3α, PGE1, PGE2, and 0.1% with 6-keto-
PGF1α. The detection limit of the assay is 4 pg/ml. 
Measurement of immunoreactive
prostaglandin E2
The PGE2 concentration in breath condensate
was measured using a specific EIA kit (Cayman
Chemical). The antiserum used in this assay has
100% cross-reactivity with PGE2, 43% with PGE3,
18.7% with PGE1, and 0.1% each with PGF2α, PGA1,
PGA2, and the detection limit at 4°C is 15 pg/ml. For
all measurements 50 μl aliquots of the condensate
were used.
Detection of hydrogen peroxide
The H2O2 was detected according to the method
of Ruch [22] and readings were expressed in μM
using the regression equation Y = (X – X0)0.0676
(where Y = micromoles of H2O2 per litre of EBC; 
X = intensity of emission; X0 = intensity of emis-
sion given by reference sample receiving distilled
water instead of EBC). For all measurements 600 μl
aliquots of condensate mixed with horseradish per-
oxidase solution (1 U/ml) were used. The H2O2 con-
centration was determined spectrofluorimetrically
using a Perkin Elmer Spectrometer (Norwalk, USA). 
Spirometry
Post-bronchodilation spirometry was performed
before the start of the treatment with inhaled
steroids in the outpatient clinic or in the hospital
(visit 1), at visit 2 and the post-therapy visit (visit 3)
and at the follow-up visit with a computer-assist-
ed spirometer (Lung Test 1000, MES Dymek,
Dabrowski SA, Kracow, Poland) according to stan-
dardized guidelines. Values were expressed as per-
centage of predicted values.
Arterial blood gases
A sample of arterialised capillary blood from the
finger pulp was taken in all COPD patients and pO2
and pCO2 were assessed to determine the presence
of respiratory failure.
Statistical analysis
Statistical analyses included a two-way analysis
of variance (ANOVA). Repeated measures test
(Friedman test) was used to compare groups. Lin-
ear regression analysis was used to assess the rela-
tionship between measured parameters. Readings
below the method detection limit were arbitrarily
assumed as half way between the detection limit
and 0. All data are expressed as means ± standard
error of the mean and significance was defined as
a p value of < 0.05. Statistica 5.1 PL for Windows
software (StatSoft Polska, Cracow, Poland) was used
for analyses. 
Results
Table II shows mean exhaled eicosanoid and
H2O2 levels from stable COPD patients (as assessed
at follow-up visit) and healthy control subjects.
Mean volume of exhaled breath condensate was
Parameter COPD  Healthy  Value 
(n = 16) (n = 11) of p
Cys-LTs [pg/ml] 41.7 ±6.83 22.4 ±3.25 < 0.02
LTB4 [pg/ml] 75.8 ±10.71 40.1 ±3.41 < 0.003
PGE2 [pg/ml] 41.1 ±2.09 20.4 ±5.21 < 0.004
8-Isoprostane [pg/ml] 60.9 ±3.84 31.3 ±4.27 < 0.001
H2O2 [mM] 0.35 ±0.029 0.17 ±0.28 < 0.001
Table II. Exhaled eicosanoids and H2O2 in stable
COPD patients and healthy subjects
Means ± standard error of the mean are shownArch Med Sci 2, April / 2012 281
Exhaled eicosanoids and biomarkers of oxidative stress in exacerbation of chronic obstructive pulmonary disease
2.22 ±0.31 ml at visit 1, 2.37 ±0.42 at visit 2, and 2.41
±0.25 at visit 3 for COPD patients. Stable COPD
patients had significantly higher levels of all
eicosanoids compared to healthy subjects.
Leukotrienes 
Significantly greater levels of exhaled cys-LTs
were observed at visit 1 compared to those at vis-
it 2 and the post-therapy visit (196.5 ±38.41 vs. 78.6
±12.28 and 50.1 ±8.15 pg/ml, p < 0.03 and p < 0.002,
respectively) and at the follow-up visit (41.7 
±6.83 pg/ml, p < 0.002) (Figure 1). There were sig-
nificantly higher levels of exhaled LTB4 at visit 1
compared to those at visit 3 but not during antibi-
otic therapy (153.6 ±25.51 vs. 132.0 ±29.31 and 71.9
±11.25 pg/ml, p < 0.03 and p < 0.05, respectively).
There was also a significant difference between lev-
els of LTB4 in exhaled breath condensate on day 1
and at the follow-up visit (75.8 ±10.71 pg/ml, 
p < 0.03). There were no differences between
cephalosporin and macrolide treated groups. 
Prostaglandin E2 
In contrast to changes in exhaled cys-LTs and
LTB4 levels, exhaled PGE2 levels did not change dur-
ing exacerbations of COPD (47.0 ±3.71 vs. 40.3 ±2.49
and 36.9 ±3.09 pg/ml, respectively, p  > 0.05) 
(Figure 3) and remained higher even at follow-up
compared to healthy subjects (41.0 ±2.09 vs. 20.4
±5.21 pg/ml, p < 0.004). There were no differences
in exhaled cys-LTs and LTB4 concentration between
cephalosporin and macrolide treated groups.
8-Isoprostane
8-isoprostane levels in expired breath conden-
sate during exacerbation of COPD are shown in 
Figure 4. There were significantly greater levels of
exhaled 8-isoprostane on day 1 compared to those
during therapy and at post-therapy visits (121.4
±14.59 vs. 92.4 ±6.28 and 56.1 ±5.15 pg/ml, p < 0.05
and p < 0.03, respectively) and at the follow-up vis-
it (60.9 ±3.84 pg/ml). There was also a significant
difference in 8-isoprostane levels between visits 
2 and 3 (p < 0.001). There were no differences
between cephalosporin and macrolide treated
groups. 
Hydrogen peroxide
As seen in Figure 5, there were significantly
greater levels of exhaled H2O2 on day 1 compared
to those during therapy and at post-therapy visits
(0.74 ±0.046 vs. 0.52 ±0.028 and 0.35 ±0.029 μM,
p < 0.001 and p < 0.001, respectively) and at the fol-
low-up visit (0.33 ±0.022 μM, p < 0.001). There was
also a significant difference in H2O2 levels between
visits 2 and 3 (p < 0.01). There were no differences
between cephalosporin and macrolide treated
groups. There was a positive correlation between
exhaled 8-isoprostane and H2O2 levels at visit 1 
(r = 0.62, p < 0.05) (Figure 6). There were no corre-
lations between exhaled eicosanoids and H2O2 and
clinical status, smoking status and pulmonary func-
tion tests at all visits.
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Figure 1. Cys-LTs in expired breath condensate of exa-
cerbated COPD patients
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Figure 2. The LTB4 in expired breath condensate of exa  -
cerbated COPD patients
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Figure 3.The PGE2in expired breath condensate of exa  -
cerbated COPD patients
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Pulmonary function tests and pO2
Significantly lower FEV1%pred. values were
observed at visit 1 compared to those at visit 2 and
the post-therapy visit (62 ±2 vs. 69 ±1 and 73 
±2 pg/ml, p < 0.001 and p < 0.001, respectively) and
at the follow-up visit (71 ±2 pg/ml, p < 0.001) 
(Figure 7 A). There were significantly lower pO2 val-
ues at visit 1 compared to those at visit 3 and during
antibiotic therapy (55 ±1 vs. 73 ±2 and 68 ±2 mm Hg,
p < 0.001 and p < 0.001, respectively). There was
also a significant difference between pO2 on day 1
and at the follow-up visit (74 ±2 mm Hg, p < 0.001)
(Figure 7 B). There were no differences between
cephalosporin and macrolide treated groups. 
Discussion 
We demonstrated that eicosanoids (cys-LTs, LTB4,
8-isoprostane) and H2O2, well known for their pro-
inflammatory activity, are significantly elevated in
patients during acute exacerbations of COPD and
that they decrease during treatment, although they
remain in higher concentrations in stable COPD
patients compared to healthy subjects. Similarly,
there are increased levels of exhaled PGE2 in
expired breath condensate from exacerbated COPD
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Figure 4. The 8-isoprostane levels in expired breath
condensate of exacerbated COPD patients
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and H2O2 levels in expired breath condensate of exa  -
cerbated COPD patients at visit 1 (day 1)
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Figure 7. Changes of FEV1 (A) and pO2 (B) in patients with exacerbation of COPD
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patients but they do not change in the course of
treatment and are significantly higher than those
from healthy subjects. 
In this study comparative measurements of pro-
inflammatory cys-LTs, LTB4, 8-isoprostanes and
H2O2 and anti-inflammatory (bronchoprotective)
PGE2 have been performed, using exhaled breath
condensate from patients with bacterial exacer-
bations of COPD, and healthy controls. Exhaled
breath condensate provides a non-invasive and
low-tech means of looking at the local inflamma-
tory process in the airways. It is very well tolerated
by patients and no adverse effects have been
reported. This technique has been used to study
oxidative stress in COPD subjects [11] and an
increasing body of evidence suggests that it is
a useful way to monitor markers of inflammation
and oxidative stress in various respiratory tract dis-
eases, such as asthma, COPD and cryptogenic
fibrosing alveolitis [23]. 
Altered metabolism of arachidonic acid may be
one of the mechanisms of bronchoconstriction in
COPD patients, particularly during exacerbation. Our
study now demonstrates local overproduction of cys-
LTs, LTB4 and PGE2 in the airways in COPD and is con-
sistent with the study showing increased plasma lev-
els of LTE4 in acute exacerbations of COPD which
decrease after steroid treatment [24]. Increased lev-
els of LTB4 have also been found in sputum from
COPD patients with α1-antitrypsin deficiency [6].
There are few data on the effects of antibiotic treat-
ment on eicosanoid profiles and it can only be spec-
ulated that both cephalosporins and roxithromycin
may reduce the number of activated cells that release
pro-inflammatory cytokines in the airways by block-
ing their influx into the lung [25]. Roxithromycin has
some immunoregulatory effects in chronic respira-
tory tract infection reflected by reducing levels of
LTB4 in epithelial lining fluid [25]. 
The fact that leukotrienes but also prostaglandins
levels are increased during exacerbations suggests
that there might be an increase in 5-lipoxygenase
enzyme activity in COPD patients. Eosinophils are
increased in bronchial mucosa in COPD during exac-
erbations compared to stable COPD and may be
responsible for increased cys-LTs. 
In contrast to elevated cys-LTs and LTB4, PGE2
levels in exhaled breath condensate of COPD
patients are high even after treatment and at fol-
low-up. It is possible that PGE2 may play a bron-
choprotective role. Moreover, PGE2 may inhibit the
release of LTB4 from neutrophils in a concentration-
dependent manner [26]. Our results clearly show
that local levels of PGE2 in the airways are increased
in COPD compared with healthy subjects and this
might be an adaptive mechanism to protect the air-
ways from bronchoconstrictive agents which, as we
show in this study, are increased even in clinically
stable subjects. Moreover, as PGE2 levels did not
change throughout the study it seems to be an
argument that a decrease in the levels of other
markers is not related to a decrease in the volume
of droplets logically expected in exacerbated
patients with increased secretions. If a changed vol-
ume of droplets produced in the airways was
responsible for observed changes in mediators, the
change would also be seen in all mediators includ-
ing PGE2.
8-Isoprostane, a stable prostaglandin-like arachi-
donate product formed on membrane phospho-
lipids by the action of reactive oxygen species, is
postulated to be a reliable biomarker of lipid per-
oxidation caused by oxygen reactive species and to
represent a quantitative measure of oxidative stress
in vivo [27]. The 8-isoprostane appears to reflect
oxidative stress in breath condensate and is pro-
gressively increased with the severity of asthma,
and its levels are particularly elevated in aspirin-
induced asthma [28]. It is also reported to be
increased in expired breath condensate in both sta-
ble and exacerbated COPD patients [19]. In this
study we found further increases in the levels of
exhaled 8-isoprostane in exacerbations of COPD
patients. It has been well documented that an oxi-
dant-antioxidant imbalance in favour of the latter
is a hallmark of COPD. 8-isoprostane levels
decreased during treatment, but remained higher
in stable COPD patients compared to healthy sub-
jects. It is not certain if 8-isoprostane is involved in
the pathogenesis of COPD, but 8-isoprostane can
cause contraction of human bronchi in vitro [29]. 
We also found an increase in H2O2 in exhaled
breath condensate during acute exacerbations of
COPD, which is in agreement with a previous study
[9]. Furthermore, there is a correlation between
exhaled H2O2 and 8-isoprostane levels, providing
further evidence that oxidative stress is increased
during exacerbation. The increased content of H2O2
and 8-isoprostane in expired breath condensate of
COPD subjects is likely to be due to increased oxi-
dant production and subsequent lipid peroxidation
in the bronchial lining fluid. This is likely to be due
to an increase in the number of activated inflam-
matory cells such as neutrophils and macrophages
in the airways. Some healthy subjects also had
measurable exhaled 8-isoprostane and H2O2, which
is consistent with studies showing the peroxide-
dependent spontaneous chemiluminescence of
human breath and with our previous study in which
22% of non-smoking subjects revealed a detectable
content of H2O2 in expired breath condensate [30]. 
Abrogation of oxidative stress and lipid peroxi-
dation in exacerbations of COPD by antibiotics may
be the effect of a reduction in the number and acti-
vation of inflammatory cells producing reactive oxy-
gen species and eicosanoids. 284 Arch Med Sci 2, April / 2012
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However, we did not find any correlations
between exhaled eicosanoids, H2O2 and 8-iso-
prostane and clinical status, smoking status and
pulmonary function tests at all visits in COPD
patients. Although there have been some trials that
showed such correlations [31], there have been
a few studies that could not find any significant
association between concentration of inflammato-
ry mediators and lung function impairment in COPD
patients measured with FEV1 [11, 31]. The lack of
correlation in our study could be due to the low
number of participants. Another explanation is that
FEV1 and inflammatory mediators are different
markers of COPD. Concentration of exhaled medi-
ators (i.e. H2O2, 8 isoprostane, leukotrienes) reflects
oxidative stress while FEV1 reflects calibre of air-
ways, and it is possible that oxidative stress is pres-
ent even without airflow limitation. The lack of cor-
relation does not diminish the importance of the
fact that the EBC mediators could be used in the
study of inflammation in the airways of patients
with COPD.
In conclusion, we have shown that there are
increased levels of both pro-inflammatory and anti-
inflammatory eicosanoids and also increased oxida-
tive stress as reflected by increased exhaled 8-iso-
prostane and H2O2 during infectious exacerbations
of COPD. Although reduced after antibiotic and anti-
inflammatory treatment, eicosanoids and markers
of oxidative stress remain in higher concentrations
locally in the airways, as reflected by the increased
levels in exhaled breath condensate of patients
with stable COPD compared to normal subjects.
These mediators may play a pathophysiological role
in COPD and measurement of these markers in the
exhaled air may provide a useful and non-invasive
approach to study inflammation in the airways dur-
ing exacerbations. 
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